. 2021 Mar 22;123(8):1773–1783. doi: 10.1002/jso.26466

Table 4.

Univariate and multivariate cox regression analysis of factors affecting OS and DFS

	OS						DFS
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Node‐positive primary tumor, n (%)	1.654	0.884–3.096	0.115				1.717	0.997–2.957	0.051	1.66	0.88–3.11	0.117
Disease‐free interval < 12 months, n (%)	1.034	0.587–1.819	0.909				1.126	0.688–1.841	0.637
Number of CRLM: >1 liver metastasis, n (%)	1.141	0.637–2.044	0.657				1.982	1.180–3.329	0.01	1.93	1.06‐3.52	0.031
Size of CRLM: Largest >50 mm, n (%)	1.86	1.036–3.339	0.038	1.08	0.51–2.31	0.835	1.246	0.714–2.173	0.438
CEA > 200	0.715	0.285–1.797	0.476				1.075	0.492–2.349	0.857
KRAS mutation	1.437	0.814–2.535	0.211				1.065	0.651–1.743	0.803
Major hepatectomy (≥3 segments)	1.755	1.024–3.007	0.041	1.57	0.84–2.95	0.158	1.583	0.997–2.513	0.052	1.51	0.88–2.57	0.13
CRS Categories (high risk vs. low risk)	1.647	0.965–2.811	0.067	1.12	0.50‐2.53	0.787	2.114	1.290–3.464	0.003	1.01	0.52–2.31	0.807
SUV_max/SUV_mean(liver) >4.3	1.637	0.961–2.786	0.07	0.899	0.40–2.03	0.797	1.289	0.812–2.047	0.281
Metabolic risk score (high risk vs. low risk)	1.968	1.133–3.421	0.016	1.45	0.50–1.19	0.489	1.83	1.089–3.075	0.022	1.186	0.46–1.94	0.873
Desmoplastic vs. nondesmoplastic	1.93	0.93–4.1	0.075	1.96	0.86–4.46	0.11	1.836	0.98–3.44	0.057	2.375	1.19–4.75	0.014
Neoadjuvant chemotherapy before primary surgery	1.433	0.837–2.454	0.19				1.229	0.761–1.985	0.4
Adjuvant chemotherapy after primary surgery	1.196	0.703–2.035	0.509				1.366	0.852–2.189	0.195
Neoadjuvant chemotherapy before LM surgery	1.209	0.591–2.473	0.604				0.87	0.499–1.518	0.625
Adjuvant chemotherapy after LM surgery	0.594	0.287–1.232	0.162				0.642	0.338–1.221	0.177

Abbreviations: DFS, disease free survival; LM, liver metastasis; mCRS, metabolic clinical risk score; OS, overall survival.